How to treat Lung cancer?

Lalela leli khasi

Indlela yokwelapha umdlavuza wamaphaphu?

Ukwelashwa komdlavuza wamaphaphu kuncike ezintweni eziningana, kuhlanganise nesigaba somdlavuza, uhlobo lomdlavuza wamaphaphu, nempilo yesiguli jikelele.

Ezinye izindlela ezivamile zokwelapha zihlanganisa:

1. Ukuhlinzwa: Ngokuvamile lokhu kuyindlela ekhethiwe yokwelapha umdlavuza wamaphaphu osesigabeni sokuqala.

Udokotela ohlinzayo ususa isimila nengxenye encane yezicubu ezinempilo ezizungezile.

2. Ukwelashwa ngemisebe: Imisebe enamandla amakhulu isetshenziselwa ukubulala amangqamuzana omdlavuza nokunciphisa izimila.

Ingasetshenziswa yodwa noma ihlanganiswe nezinye izindlela zokwelapha.

3. Ukwelashwa ngamakhemikhali: Lokhu kwelashwa kusebenzisa imithi yokubulala amangqamuzana omdlavuza.

Inganikezwa ngemithambo yegazi noma ngomlomo, futhi ivame ukusetshenziswa ngokuhlanganiswa nezinye izindlela zokwelapha.

4. Ukwelashwa okuhlosiwe: Lokhu kwelashwa kuhloselwe izakhi zofuzo noma amaprotheni athile abamba iqhaza ekukhuleni nasekusindeni kwamangqamuzana omdlavuza.

Ngokuvamile isetshenziselwa umdlavuza wamaphaphu osethuthukile noma osakazekile.

5. Ukwelashwa nge-immunotherapy: Lokhu kwelashwa kusiza isimiso somzimba sokuzivikela komzimba ukuba sibone futhi sihlasele amangqamuzana omdlavuza.

Ngokuvamile isetshenziselwa umdlavuza wamaphaphu osethuthukile noma osakazekile.

6. Ukwelashwa nge-photodynamic: Lokhu kwelashwa kusebenzisa umuthi osebenza ngokukhanya ukubulala amangqamuzana omdlavuza.

Ngokuvamile isetshenziselwa umdlavuza wamaphaphu osesigabeni sokuqala.

7. Ukwelashwa ngama-proton: Lolu uhlobo lokwelashwa ngemisebe olusebenzisa ama-proton esikhundleni semisebe ye-X ukuze kufakwe imisebe etumor.

Ngokuvamile isetshenziselwa umdlavuza wamaphaphu osesigabeni sokuqala.

8. Ukuhlolwa komtholampilo: Iziguli zingase zifaneleke ukubamba iqhaza ekuhlolweni komtholampilo okuhlola ukwelashwa okusha noma inhlanganisela yokwelashwa.

Kubalulekile ukuxoxa ngamathuba amahle kakhulu okwelashwa neqembu lezokunakekelwa kwempilo, njengoba uhlelo lokwelashwa olusebenza kahle kakhulu luzoncika esimweni somuntu ngamunye.

Izikhombo

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.

Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.

Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.

Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.

Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.

Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.

Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.

Ukuzikhulula: kwezokwelapha

Le webhusayithi inikezwa ngezinjongo zemfundo nezokwaziswa kuphela futhi ayifaki ukunikeza izeluleko zezokwelapha noma izinsizakalo zobungcweti.

Imininingwane enikeziwe akufanele isetshenziselwe ukuxilonga noma ukwelapha inkinga noma isifo, futhi labo abafuna iseluleko somuntu siqu sezokwelapha kufanele babonane nodokotela onelayisense.

Sicela uqaphele ukuthi inethiwekhi ye-neural ekhiqiza izimpendulo zemibuzo, ayinembile ngokukhethekile uma kuziwa kokuqukethwe kwezinombolo. Ngokwesibonelo, inani labantu abanesifo esithile.

Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo ofanelekayo mayelana nesimo sezokwelapha. Ungalokothi ungayinaki iseluleko sezokwelapha sobungcweti noma ubambezele ukusifuna ngenxa yento oyifundile kule webhusayithi. Uma ucabanga ukuthi ungase ube nesimo esiphuthumayo sezokwelapha, shayela i-911 noma uye egumbini lezimo eziphuthumayo eliseduze ngokushesha. Ayikho ubudlelwano bokuthi udokotela-isiguli obakhiwe yile webhusayithi noma ukusetshenziswa kwayo. I-BioMedLib noma abasebenzi bayo, noma noma yimuphi umnikeli wale webhusayithi, akenzi noma yimiphi imibono, ecacile noma ecacile, mayelana nolwazi olunikezwe lapha noma ukusetshenziswa kwayo.

Ukuzikhulula: amalungelo obunikazi

I-Digital Millennium Copyright Act ka-1998, i-17 U.S.C. § 512 (i- DMCA) inikeza indlela yokuphendula kubanikazi bamalungelo obunikazi abakholelwa ukuthi okokusebenza okubonakala kwi-Internet kwephula amalungelo abo ngaphansi komthetho we-copyright wase-US.

Uma ukholelwa ngobuqotho ukuthi noma yikuphi okuqukethwe noma okokusebenza okwenziwe kutholakale maqondana newebhusayithi yethu noma izinsizakalo kwephula ilungelo lakho lobunikazi, wena (noma umenzeli wakho) ungasithumela isaziso esicela ukuthi okuqukethwe noma okokusebenza kususwe, noma ukufinyelela kukho kuvinjelwe.

Izaziso kufanele zithunyelwe ngokubhala nge-imeyili (bheka isigaba esithi "Contact" ukuze uthole ikheli le-imeyili).

I-DMCA idinga ukuthi isaziso sakho sokwephulwa kwamalungelo obunikazi kubandakanye imininingwane elandelayo: (1) incazelo yomsebenzi onamalungelo obunikazi oyisihloko sokwephulwa okusolwa; (2) incazelo yokuqukethwe okusolwa ukwephula amalungelo obunikazi nolwazi olwanele ukusivumela ukuthi sithole okuqukethwe; (3) imininingwane yokuxhumana nawe, kufaka phakathi ikheli lakho, inombolo yocingo nekheli le-imeyili; (4) isitatimende sakho sokuthi unokholo oluhle lokuthi okuqukethwe ngendlela ekhonjiwe ngayo akugunyaziwe ngumnikazi wamalungelo obunikazi, noma umenzeli wakhe, noma ngokusebenza kwanoma imuphi umthetho;

(5) isitatimende sakho, esisayinwe ngaphansi kwesijeziso sokufakaza amanga, sokuthi ukwaziswa okusesazisweni kunembile nokuthi unegunya lokuphoqelela amalungelo obunikazi okuthiwa aphuliwe;

futhi (6) isignesha ebonakalayo noma ye-elekthronikhi yomnikazi we-copyright noma umuntu ogunyaziwe ukuba asebenze egameni lomnikazi we-copyright.

Ukwehluleka ukufaka yonke imininingwane engenhla kungaholela ekubambezelweni kokucutshungulwa kwesikhalazo sakho.

Othintana naye

Sicela usithumelele i-imeyili nganoma yimiphi imibuzo / iziphakamiso.

How to treat lung cancer?

The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.

Some common treatment options include:

1. Surgery: This is often the preferred treatment for early-stage lung cancer.

The surgeon removes the tumor and a small portion of healthy tissue around it.

2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.

It can be used alone or in combination with other treatments.

3. Chemotherapy: This treatment uses drugs to kill cancer cells.

It can be given intravenously or or orally, and is often used in combination with other treatments.

4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.

It is often used for advanced or metastatic lung cancer.

5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.

It is often used for advanced or metastatic lung cancer.

6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.

It is often used for early-stage lung cancer.

7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.

It is often used for early-stage lung cancer.

8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.

It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.